Osteosarcoma overview: Difference between revisions
No edit summary |
No edit summary |
||
| Line 7: | Line 7: | ||
== Historical perspective == | == Historical perspective == | ||
[[Osteosarcoma]] is known as the most common bone malignant tumor. [[Osteosarcoma]] is an ancient disease and is not completely understood, yet. Nobody knows when and who discovered Osteosarcoma, but recent Paleontology discoveries revealed that [[Osteosarcoma]] has a long story in planet earth. Resent discoverers in Germany revealed a 240 million-year-old highly malignant tumor in the fossilized leg bone of a stem turtle<ref name="pmid30730547">{{cite journal |vauthors=Haridy Y, Witzmann F, Asbach P, Schoch RR, Fröbisch N, Rothschild BM |title=Triassic Cancer-Osteosarcoma in a 240-Million-Year-Old Stem-Turtle |journal=JAMA Oncol |volume= |issue= |pages= |date=February 2019 |pmid=30730547 |doi=10.1001/jamaoncol.2018.6766 |url=}}</ref>. Its been found that osteosarcoma is the earliest case of human cancer which was found on the 1.7 million-year-old fossil of an early ancestor of mankind in Swartkrans cave in South Africa<ref name="pmid27990273">{{cite journal |vauthors=Bielack SS, Hecker-Nolting S, Blattmann C, Kager L |title=Advances in the management of osteosarcoma |journal=F1000Res |volume=5 |issue= |pages=2767 |date=2016 |pmid=27990273 |pmc=5130082 |doi=10.12688/f1000research.9465.1 |url=}}</ref>. In 1990, a thousand-year-old mummy of a woman in her mid-30s of age had with a malignant tumor in her upper-left arm which that mass had grown so large that it might burst through her skin while she was still alive. | |||
==Classification== | ==Classification== | ||
[[Osteosarcoma]] (OS) is a rare bone cancer which affects both adolescents and young adults. Osteosarcoma was classified as primary and secondary. Later the the [[World Health Organization]] sub-typed as intramedullry/central and surface osteosarcoma with a number of sub-types under each group<ref name="pmid24002129">{{cite journal |vauthors=Duong LM, Richardson LC |title=Descriptive epidemiology of malignant primary osteosarcoma using population-based registries, United States, 1999-2008 |journal=J Registry Manag |volume=40 |issue=2 |pages=59–64 |date=2013 |pmid=24002129 |pmc=4476493 |doi= |url=}}</ref>. | |||
==Pathophysiology== | ==Pathophysiology== | ||
The | The main cause of [[osteosarcoma]] is not well-known, yet. However, a number of risk factors have been identified in this regard. [[Osteosarcoma]] can involve any bone but it usually affects the extremities of long bones near metaphyseal growth plates. The most common sites include | ||
* Femur 42% of cases ( the distal femur had around 75% of involvement). | |||
* Tibia 19% of cases ( the proximal tibia had around 80% of involvement). | |||
* Humerus 10% of cases ( the proximal humerus had around 90% of involvement). | |||
* Skull and jaw 8% of cases. | |||
* Pelvis 8% of cases. | |||
==Causes== | ==Causes== | ||
There are no established causes for osteosarcoma. However, some studies show that an increased level of [[C-Fos|c-fos]] [[proto-oncogene]] expression can lead to osteosarcoma. | There are no established causes for osteosarcoma. However, some studies show that an increased level of [[C-Fos|c-fos]] [[proto-oncogene]] expression can lead to osteosarcoma. | ||
==Differential Diagnosis== | ==Differential Diagnosis== | ||
Osteosarcoma must be differentiated from | Osteosarcoma must be differentiated from other diseases such as: any type of bone lesions caused by infection and/or tumors. Features such as the eccentric location of the tumor in the metaphyseal portion of the bone and the skeletal location help to distinguish osteosarcoma from Ewing sarcoma. Bone metastases from other primary tumours, less frequent in the young than in adult patients, should also be considered. | ||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
Osteosarcoma is the most common | Osteosarcoma is the most common nonhematologic primary malignant bone neoplasm causing 35% of primary bone malignancies and occurs at any age, it usually affects patients in the second and third decade of life with a peak incidence between 13 and 16 years of age. It is the 8th leading cancer in children under age 15, comprising 2.4% of all malignancies in pediatric patients and about 20% of all primary bone cancers. The overall incidence of osteosarcoma in U.S. population under 24 years of age are estimated at 0.44 cases for 100,000 individuals. Osteosarcoma is slightly more common in males than in females. Primary osteosarcoma typically occurs in young patients (10-20 years) with 75% occurring before the age of 20. Secondary osteosarcoma occurs in elderly patients<ref name="pmid25889105">{{cite journal |vauthors=Foley JM, Scholten DJ, Monks NR, Cherba D, Monsma DJ, Davidson P, Dylewski D, Dykema K, Winn ME, Steensma MR |title=Anoikis-resistant subpopulations of human osteosarcoma display significant chemoresistance and are sensitive to targeted epigenetic therapies predicted by expression profiling |journal=J Transl Med |volume=13 |issue= |pages=110 |date=April 2015 |pmid=25889105 |pmc=4419490 |doi=10.1186/s12967-015-0466-4 |url=}}</ref><ref name="pmid30923668">{{cite journal |vauthors=Huang X, Zhao J, Bai J, Shen H, Zhang B, Deng L, Sun C, Liu Y, Zhang J, Zheng J |title=Risk and clinicopathological features of osteosarcoma metastasis to the lung: A population-based study |journal=J Bone Oncol |volume=16 |issue= |pages=100230 |date=June 2019 |pmid=30923668 |pmc=6423404 |doi=10.1016/j.jbo.2019.100230 |url=}}</ref><ref name="pmid29065898">{{cite journal |vauthors=Simpson S, Dunning MD, de Brot S, Grau-Roma L, Mongan NP, Rutland CS |title=Comparative review of human and canine osteosarcoma: morphology, epidemiology, prognosis, treatment and genetics |journal=Acta Vet. Scand. |volume=59 |issue=1 |pages=71 |date=October 2017 |pmid=29065898 |pmc=5655853 |doi=10.1186/s13028-017-0341-9 |url=}}</ref><ref name="pmid25070231">{{cite journal |vauthors=Moore DD, Luu HH |title=Osteosarcoma |journal=Cancer Treat. Res. |volume=162 |issue= |pages=65–92 |date=2014 |pmid=25070231 |doi=10.1007/978-3-319-07323-1_4 |url=}}</ref>. | ||
==Risk Factors== | |||
Common risk factors in the development of osteosarcoma are radiation to bones, alkylating antineoplastic agents, Paget disease, multiple hereditary osteochondromas, fibrous dysplasia, Bloom syndrome,Rothmund-Thomson syndrome, and Li-Fraumeni syndrome<ref name="pmid27986268">{{cite journal |vauthors=Stern N, Sakji I, Defachelles AS, Lervat C, Ryckewaert T, Marliot G, Peugniez C, Deplanque D, Penel N |title=[Incidence and risk factors for ifosfamide-related encephalopathy in sarcoma patients] |language=French |journal=Bull Cancer |volume=104 |issue=3 |pages=208–212 |date=March 2017 |pmid=27986268 |doi=10.1016/j.bulcan.2016.11.007 |url=}}</ref><ref name="pmid27860191">{{cite journal |vauthors=Endicott AA, Morimoto LM, Kline CN, Wiemels JL, Metayer C, Walsh KM |title=Perinatal factors associated with clinical presentation of osteosarcoma in children and adolescents |journal=Pediatr Blood Cancer |volume=64 |issue=6 |pages= |date=June 2017 |pmid=27860191 |doi=10.1002/pbc.26349 |url=}}</ref><ref name="pmid23824394">{{cite journal |vauthors=Miller BJ, Cram P, Lynch CF, Buckwalter JA |title=Risk factors for metastatic disease at presentation with osteosarcoma: an analysis of the SEER database |journal=J Bone Joint Surg Am |volume=95 |issue=13 |pages=e89 |date=July 2013 |pmid=23824394 |pmc=3689260 |doi=10.2106/JBJS.L.01189 |url=}}</ref><ref name="pmid26400284">{{cite journal |vauthors=Zhang HF, Yan JP, Zhuang YS, Han GQ |title=Association between angiogenic growth factor genetic polymorphisms and the risk of osteosarcoma |journal=Genet. Mol. Res. |volume=14 |issue=3 |pages=10524–9 |date=September 2015 |pmid=26400284 |doi=10.4238/2015.September.8.14 |url=}}</ref>. | |||
==Screening== | ==Screening== | ||
According to the the U.S. Preventive Service Task Force (USPSTF), there is insufficient evidence to recommend routine screening for osteosarcoma.<ref>Osteosarcoma. U.S. Preventive Services Task Force.http://www.uspreventiveservicestaskforce.org/BrowseRec/Search?s=osteosarcoma</ref> | According to the the U.S. Preventive Service Task Force (USPSTF), there is insufficient evidence to recommend routine screening for osteosarcoma.<ref>Osteosarcoma. U.S. Preventive Services Task Force.http://www.uspreventiveservicestaskforce.org/BrowseRec/Search?s=osteosarcoma</ref> | ||
==Natural History, Complications and Prognosis== | ==Natural History, Complications and Prognosis<ref name="pmid29115164">{{cite journal |vauthors=Liu W, Zhao X, Zhang YJ, Fang GW, Xue Y |title=MicroRNA-375 as a potential serum biomarker for the diagnosis, prognosis, and chemosensitivity prediction of osteosarcoma |journal=J. Int. Med. Res. |volume=46 |issue=3 |pages=975–983 |date=March 2018 |pmid=29115164 |pmc=5972241 |doi=10.1177/0300060517734114 |url=}}</ref><ref name="pmid26665241">{{cite journal |vauthors=Friebele JC, Peck J, Pan X, Abdel-Rasoul M, Mayerson JL |title=Osteosarcoma: A Meta-Analysis and Review of the Literature |journal=Am J. Orthop. |volume=44 |issue=12 |pages=547–53 |date=December 2015 |pmid=26665241 |doi= |url=}}</ref><ref name="pmid24345772">{{cite journal |vauthors=Luetke A, Meyers PA, Lewis I, Juergens H |title=Osteosarcoma treatment - where do we stand? A state of the art review |journal=Cancer Treat. Rev. |volume=40 |issue=4 |pages=523–32 |date=May 2014 |pmid=24345772 |doi=10.1016/j.ctrv.2013.11.006 |url=}}</ref><ref name="pmid27037440">{{cite journal |vauthors=Parry MC, Laitinen M, Albergo J, Jeys L, Carter S, Gaston CL, Sumathi V, Grimer RJ |title=Osteosarcoma of the pelvis |journal=Bone Joint J |volume=98-B |issue=4 |pages=555–63 |date=April 2016 |pmid=27037440 |doi=10.1302/0301-620X.98B4.36583 |url=}}</ref><ref name="pmid25022788">{{cite journal |vauthors=Yonemoto T, Hosono A, Iwata S, Kamoda H, Hagiwara Y, Fujiwara T, Kawai A, Ishii T |title=The prognosis of osteosarcoma occurring as second malignancy of childhood cancers may be favorable: experience of two cancer centers in Japan |journal=Int. J. Clin. Oncol. |volume=20 |issue=3 |pages=613–6 |date=June 2015 |pmid=25022788 |doi=10.1007/s10147-014-0729-8 |url=}}</ref><ref name="pmid27651036">{{cite journal |vauthors=Kager L, Tamamyan G, Bielack S |title=Novel insights and therapeutic interventions for pediatric osteosarcoma |journal=Future Oncol |volume=13 |issue=4 |pages=357–368 |date=February 2017 |pmid=27651036 |doi=10.2217/fon-2016-0261 |url=}}</ref>== | ||
Common [[Complication (medicine)|complications]] of osteosarcoma include [[Bone fracture|pathologic fracture]] and [[metastasis]]. Pre-treatment factors that influence outcome of the osteosarcoma are primary tumor site, size of the primary tumor, and site of [[metastasis]]. After administration of preoperative [[chemotherapy]], factors that influence outcome of the osteosarcoma are adequacy of tumor resection and [[necrosis]] following induction or [[neoadjuvant chemotherapy]]. The 5 year survival rate of osteosarcoma after adequate therapy is approximately 60-80%. | Common [[Complication (medicine)|complications]] of osteosarcoma include [[Bone fracture|pathologic fracture]] and [[metastasis]]. Pre-treatment factors that influence outcome of the osteosarcoma are primary tumor site, size of the primary tumor, and site of [[metastasis]]. After administration of preoperative [[chemotherapy]], factors that influence outcome of the osteosarcoma are adequacy of tumor resection and [[necrosis]] following induction or [[neoadjuvant chemotherapy]]. The 5 year survival rate of osteosarcoma after adequate therapy is approximately 60-80%. | ||
==Diagnosis== | ==Diagnosis== | ||
===Staging=== | ===Staging=== | ||
According to the American Joint Committee on Cancer (AJCC), there are four stages of osteosarcoma based on the size of primary tumor, [[metastasis]], involvement of [[lymph nodes]], and grade of the tumor. For the purpose of treatment, there are only two stages of high-grade osteosarcoma: [[Localized disease|localized]] osteosarcoma and [[metastatic]] osteosarcoma. | According to the American Joint Committee on Cancer (AJCC), there are four stages of osteosarcoma based on the size of primary tumor, [[metastasis]], involvement of [[lymph nodes]], and grade of the tumor. For the purpose of treatment, there are only two stages of high-grade osteosarcoma: [[Localized disease|localized]] osteosarcoma and [[metastatic]] osteosarcoma<ref name="pmid25070231">{{cite journal |vauthors=Moore DD, Luu HH |title=Osteosarcoma |journal=Cancer Treat. Res. |volume=162 |issue= |pages=65–92 |date=2014 |pmid=25070231 |doi=10.1007/978-3-319-07323-1_4 |url=}}</ref><ref name="pmid28195881">{{cite journal |vauthors=Cates JM |title=Comparison of the AJCC, MSTS, and Modified Spanier Systems for Clinical and Pathologic Staging of Osteosarcoma |journal=Am. J. Surg. Pathol. |volume=41 |issue=3 |pages=405–413 |date=March 2017 |pmid=28195881 |doi=10.1097/PAS.0000000000000774 |url=}}</ref><ref name="pmid29182106">{{cite journal |vauthors=Biazzo A, De Paolis M |title=Multidisciplinary approach to osteosarcoma |journal=Acta Orthop Belg |volume=82 |issue=4 |pages=690–698 |date=December 2016 |pmid=29182106 |doi= |url=}}</ref><ref name="pmid29200101">{{cite journal |vauthors=Cates JMM |title=Modeling Continuous Prognostic Factors in Survival Analysis: Implications for Tumor Staging and Assessing Chemotherapy Effect in Osteosarcoma |journal=Am. J. Surg. Pathol. |volume=42 |issue=4 |pages=485–491 |date=April 2018 |pmid=29200101 |doi=10.1097/PAS.0000000000000995 |url=}}</ref><ref name="pmid27138473">{{cite journal |vauthors=Jeys LM, Thorne CJ, Parry M, Gaston CL, Sumathi VP, Grimer JR |title=A Novel System for the Surgical Staging of Primary High-grade Osteosarcoma: The Birmingham Classification |journal=Clin. Orthop. Relat. Res. |volume=475 |issue=3 |pages=842–850 |date=March 2017 |pmid=27138473 |pmc=5289182 |doi=10.1007/s11999-016-4851-y |url=}}</ref>. | ||
===History and Symptoms=== | ===History and Symptoms=== | ||
The most common symptoms of osteosarcoma include [[bone pain]] that may worse at night, [[swelling]], and [[redness]] at the site of the tumor. The affected bone is not as strong as normal bones and may fracture with minor trauma (a pathological fracture). | The most common symptoms of osteosarcoma include [[bone pain]] that may worse at night, [[swelling]], and [[redness]] at the site of the tumor. The affected bone is not as strong as normal bones and may fracture with minor trauma (a pathological fracture)<ref name="pmid25070231">{{cite journal |vauthors=Moore DD, Luu HH |title=Osteosarcoma |journal=Cancer Treat. Res. |volume=162 |issue= |pages=65–92 |date=2014 |pmid=25070231 |doi=10.1007/978-3-319-07323-1_4 |url=}}</ref><ref name="pmid29182106">{{cite journal |vauthors=Biazzo A, De Paolis M |title=Multidisciplinary approach to osteosarcoma |journal=Acta Orthop Belg |volume=82 |issue=4 |pages=690–698 |date=December 2016 |pmid=29182106 |doi= |url=}}</ref><ref name="pmid29492676">{{cite journal |vauthors=Kumar R, Kumar M, Malhotra K, Patel S |title=Primary Osteosarcoma in the Elderly Revisited: Current Concepts in Diagnosis and Treatment |journal=Curr Oncol Rep |volume=20 |issue=2 |pages=13 |date=February 2018 |pmid=29492676 |doi=10.1007/s11912-018-0658-1 |url=}}</ref>. | ||
===Physical Examination=== | ===Physical Examination=== | ||
Physical examination findings will depend on the location of the osteosarcoma. Common physical examination findings of osteosarcoma are localized [[swelling]] and [[tenderness]] at the site of the tumor. | Physical examination findings will depend on the location of the osteosarcoma. Common physical examination findings of osteosarcoma are localized [[swelling]] and [[tenderness]] at the site of the tumor<ref name="pmid19915470">{{cite journal |vauthors=Kim HJ, Chalmers PN, Morris CD |title=Pediatric osteogenic sarcoma |journal=Curr. Opin. Pediatr. |volume=22 |issue=1 |pages=61–6 |date=February 2010 |pmid=19915470 |doi=10.1097/MOP.0b013e328334581f |url=}}</ref><ref name="pmid25070231">{{cite journal |vauthors=Moore DD, Luu HH |title=Osteosarcoma |journal=Cancer Treat. Res. |volume=162 |issue= |pages=65–92 |date=2014 |pmid=25070231 |doi=10.1007/978-3-319-07323-1_4 |url=}}</ref><ref name="pmid20179183">{{cite journal |vauthors=Ilaslan H, Schils J, Nageotte W, Lietman SA, Sundaram M |title=Clinical presentation and imaging of bone and soft-tissue sarcomas |journal=Cleve Clin J Med |volume=77 Suppl 1 |issue= |pages=S2–7 |date=March 2010 |pmid=20179183 |doi=10.3949/ccjm.77.s1.01 |url=}}</ref><ref name="pmid21037356">{{cite journal |vauthors=Wu PK, Chen WM, Lee OK, Chen CF, Huang CK, Chen TH |title=The prognosis for patients with osteosarcoma who have received prior manipulative therapy |journal=J Bone Joint Surg Br |volume=92 |issue=11 |pages=1580–5 |date=November 2010 |pmid=21037356 |doi=10.1302/0301-620X.92B11.24706 |url=}}</ref><ref name="pmid29980176">{{cite journal |vauthors=Obiedat H, Alrabadi N, Sultan E, Al Shatti M, Zihlif M |title=The effect of ERCC1 and ERCC2 gene polymorphysims on response to cisplatin based therapy in osteosarcoma patients |journal=BMC Med. Genet. |volume=19 |issue=1 |pages=112 |date=July 2018 |pmid=29980176 |pmc=6035436 |doi=10.1186/s12881-018-0627-4 |url=}}</ref>. | ||
===Laboratory Findings=== | ===Laboratory Findings=== | ||
Laboratory tests for osteosarcoma include [[complete blood count]] (CBC), serum [[alkaline phosphatase]] and [[lactate dehydrogenase]]. | Laboratory tests for osteosarcoma include [[complete blood count]] (CBC), serum [[alkaline phosphatase]] and [[lactate dehydrogenase]]<ref name="pmid19915470">{{cite journal |vauthors=Kim HJ, Chalmers PN, Morris CD |title=Pediatric osteogenic sarcoma |journal=Curr. Opin. Pediatr. |volume=22 |issue=1 |pages=61–6 |date=February 2010 |pmid=19915470 |doi=10.1097/MOP.0b013e328334581f |url=}}</ref><ref name="pmid25070231">{{cite journal |vauthors=Moore DD, Luu HH |title=Osteosarcoma |journal=Cancer Treat. Res. |volume=162 |issue= |pages=65–92 |date=2014 |pmid=25070231 |doi=10.1007/978-3-319-07323-1_4 |url=}}</ref><ref name="pmid20179183">{{cite journal |vauthors=Ilaslan H, Schils J, Nageotte W, Lietman SA, Sundaram M |title=Clinical presentation and imaging of bone and soft-tissue sarcomas |journal=Cleve Clin J Med |volume=77 Suppl 1 |issue= |pages=S2–7 |date=March 2010 |pmid=20179183 |doi=10.3949/ccjm.77.s1.01 |url=}}</ref><ref name="pmid21037356">{{cite journal |vauthors=Wu PK, Chen WM, Lee OK, Chen CF, Huang CK, Chen TH |title=The prognosis for patients with osteosarcoma who have received prior manipulative therapy |journal=J Bone Joint Surg Br |volume=92 |issue=11 |pages=1580–5 |date=November 2010 |pmid=21037356 |doi=10.1302/0301-620X.92B11.24706 |url=}}</ref><ref name="pmid29980176">{{cite journal |vauthors=Obiedat H, Alrabadi N, Sultan E, Al Shatti M, Zihlif M |title=The effect of ERCC1 and ERCC2 gene polymorphysims on response to cisplatin based therapy in osteosarcoma patients |journal=BMC Med. Genet. |volume=19 |issue=1 |pages=112 |date=July 2018 |pmid=29980176 |pmc=6035436 |doi=10.1186/s12881-018-0627-4 |url=}}</ref>. | ||
===Biopsy=== | ===Biopsy=== | ||
Revision as of 12:02, 3 April 2019
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohammadmain Rezazadehsaatlou[2].
|
Osteosarcoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Osteosarcoma overview On the Web |
|
American Roentgen Ray Society Images of Osteosarcoma overview |
Overview
Bone cancer is a malignant (cancerous) tumor of the bone that destroys normal bone tissue. Osteosarcoma is the most common type of malignant bone cancer, accounting for 35% of primary bone malignancies. It is a malignant tumor that is characterized by the direct formation of bone or osteoid tissue by the tumor cells. Malignant tumors that begin in bone tissue are called primary bone cancer. Osteosarcoma may be classified according to the World Health Organization’s histologic classification of bone tumors into three groups. The osteosarcomas may be localized at the end of the long bones (commonly in the metaphysis). Most often it affects the upper end of the tibia, humerus, or lower end of the femur. On gross pathology, areas of bone formation, hemorrhage, fibrosis, and cystic degeneration on cut surface are characteristic findings of osteosarcoma. On microscopic histopathological analysis, presence of osteoid within the tumor, pleomorphic cells, anaplastic cells, and atypical mitoses are characteristic findings of osteosarcoma. There are no established causes for osteosarcoma. The common risk factors in the development of osteosarcoma are radiation to bones, alkylating antineoplastic agents, Paget disease, multiple hereditary osteochondromas, fibrous dysplasia, Bloom syndrome, Rothmund-Thomson syndrome, and Li-Fraumeni syndrome. Common complications of osteosarcoma include pathologic fracture and metastasis. The most common symptoms of osteosarcoma include bone pain that may be worse at night, swelling, and redness at the site of the tumor. On x-ray, osteosarcoma is characterized by medullary and cortical bone destruction, periosteal reaction, tumor matrix calcification, and soft tissue mass. On MRI, osteosarcoma is characterized by intermediate intensity of soft tissue and low signal intensity of ossified components on T1. High signal intensity of soft tissue and low signal intensity of ossified components on T2. The predominant therapy for osteosarcoma is neoadjuvant chemotherapy (chemotherapy given before surgery) followed by surgical resection. The most common drugs used to treat osteosarcoma are cisplatin, doxorubicin and high-dose methotrexate.
Historical perspective
Osteosarcoma is known as the most common bone malignant tumor. Osteosarcoma is an ancient disease and is not completely understood, yet. Nobody knows when and who discovered Osteosarcoma, but recent Paleontology discoveries revealed that Osteosarcoma has a long story in planet earth. Resent discoverers in Germany revealed a 240 million-year-old highly malignant tumor in the fossilized leg bone of a stem turtle[1]. Its been found that osteosarcoma is the earliest case of human cancer which was found on the 1.7 million-year-old fossil of an early ancestor of mankind in Swartkrans cave in South Africa[2]. In 1990, a thousand-year-old mummy of a woman in her mid-30s of age had with a malignant tumor in her upper-left arm which that mass had grown so large that it might burst through her skin while she was still alive.
Classification
Osteosarcoma (OS) is a rare bone cancer which affects both adolescents and young adults. Osteosarcoma was classified as primary and secondary. Later the the World Health Organization sub-typed as intramedullry/central and surface osteosarcoma with a number of sub-types under each group[3].
Pathophysiology
The main cause of osteosarcoma is not well-known, yet. However, a number of risk factors have been identified in this regard. Osteosarcoma can involve any bone but it usually affects the extremities of long bones near metaphyseal growth plates. The most common sites include
- Femur 42% of cases ( the distal femur had around 75% of involvement).
- Tibia 19% of cases ( the proximal tibia had around 80% of involvement).
- Humerus 10% of cases ( the proximal humerus had around 90% of involvement).
- Skull and jaw 8% of cases.
- Pelvis 8% of cases.
Causes
There are no established causes for osteosarcoma. However, some studies show that an increased level of c-fos proto-oncogene expression can lead to osteosarcoma.
Differential Diagnosis
Osteosarcoma must be differentiated from other diseases such as: any type of bone lesions caused by infection and/or tumors. Features such as the eccentric location of the tumor in the metaphyseal portion of the bone and the skeletal location help to distinguish osteosarcoma from Ewing sarcoma. Bone metastases from other primary tumours, less frequent in the young than in adult patients, should also be considered.
Epidemiology and Demographics
Osteosarcoma is the most common nonhematologic primary malignant bone neoplasm causing 35% of primary bone malignancies and occurs at any age, it usually affects patients in the second and third decade of life with a peak incidence between 13 and 16 years of age. It is the 8th leading cancer in children under age 15, comprising 2.4% of all malignancies in pediatric patients and about 20% of all primary bone cancers. The overall incidence of osteosarcoma in U.S. population under 24 years of age are estimated at 0.44 cases for 100,000 individuals. Osteosarcoma is slightly more common in males than in females. Primary osteosarcoma typically occurs in young patients (10-20 years) with 75% occurring before the age of 20. Secondary osteosarcoma occurs in elderly patients[4][5][6][7].
Risk Factors
Common risk factors in the development of osteosarcoma are radiation to bones, alkylating antineoplastic agents, Paget disease, multiple hereditary osteochondromas, fibrous dysplasia, Bloom syndrome,Rothmund-Thomson syndrome, and Li-Fraumeni syndrome[8][9][10][11].
Screening
According to the the U.S. Preventive Service Task Force (USPSTF), there is insufficient evidence to recommend routine screening for osteosarcoma.[12]
Natural History, Complications and Prognosis[13][14][15][16][17][18]
Common complications of osteosarcoma include pathologic fracture and metastasis. Pre-treatment factors that influence outcome of the osteosarcoma are primary tumor site, size of the primary tumor, and site of metastasis. After administration of preoperative chemotherapy, factors that influence outcome of the osteosarcoma are adequacy of tumor resection and necrosis following induction or neoadjuvant chemotherapy. The 5 year survival rate of osteosarcoma after adequate therapy is approximately 60-80%.
Diagnosis
Staging
According to the American Joint Committee on Cancer (AJCC), there are four stages of osteosarcoma based on the size of primary tumor, metastasis, involvement of lymph nodes, and grade of the tumor. For the purpose of treatment, there are only two stages of high-grade osteosarcoma: localized osteosarcoma and metastatic osteosarcoma[7][19][20][21][22].
History and Symptoms
The most common symptoms of osteosarcoma include bone pain that may worse at night, swelling, and redness at the site of the tumor. The affected bone is not as strong as normal bones and may fracture with minor trauma (a pathological fracture)[7][20][23].
Physical Examination
Physical examination findings will depend on the location of the osteosarcoma. Common physical examination findings of osteosarcoma are localized swelling and tenderness at the site of the tumor[24][7][25][26][27].
Laboratory Findings
Laboratory tests for osteosarcoma include complete blood count (CBC), serum alkaline phosphatase and lactate dehydrogenase[24][7][25][26][27].
Biopsy
Biopsy of osteosarcoma is important for confirming the diagnosis and for determining the histologic subtype.[28] Biopsy may be performed percutaneously with either a fine-needle, or a wide-bore needle, or through a formal incision.
X Ray
On x-ray, osteosarcoma is characterized by medullary and cortical bone destruction, periosteal reaction, tumor matrix calcification, and soft tissue mass.[29]
CT
CT scan in osteosarcoma may be helpful in biopsy and staging. CT scan adds little to plain radiography and MRI in direct assessment of the tumor.[30]
MRI
On MRI, osteosarcoma is characterized by intermediate intensity of soft tissue and low signal intensity of ossified components on T1. High signal intensity of soft tissue and low signal intensity of ossified components on T2. Considerable contrast enhancement of solid components on T1 contrast.
Other Imaging Findings
Bone scan in osteosarcoma is used to observe abnormal areas of bone and metastasis.[31]
Other Diagnostic Studies
No additional tests are recommended for the diagnosis of osteosarcoma.
Treatment
Medical Therapy
The predominant therapy for osteosarcoma is neoadjuvant chemotherapy (chemotherapy given before surgery) followed by surgical resection. The most common drugs used to treat osteosarcoma are cisplatin, doxorubicin and high-dose methotrexate. Ifosfamide can be used as an adjuvant treatment if the necrosis rate is low. Samarium is a radioactive drug that targets areas where bone cells are growing, such as tumor cells in the bone. It helps relieve bone pain.
Surgery
The mainstay of therapy for osteosarcoma is surgical resection. Rather than using the standard staging system, a simpler system is often used when planning treatment for osteosarcoma. This system divides osteosarcomas into 2 groups: localized osteosarcoma and metastatic osteosarcoma.
References
- ↑ Haridy Y, Witzmann F, Asbach P, Schoch RR, Fröbisch N, Rothschild BM (February 2019). "Triassic Cancer-Osteosarcoma in a 240-Million-Year-Old Stem-Turtle". JAMA Oncol. doi:10.1001/jamaoncol.2018.6766. PMID 30730547.
- ↑ Bielack SS, Hecker-Nolting S, Blattmann C, Kager L (2016). "Advances in the management of osteosarcoma". F1000Res. 5: 2767. doi:10.12688/f1000research.9465.1. PMC 5130082. PMID 27990273.
- ↑ Duong LM, Richardson LC (2013). "Descriptive epidemiology of malignant primary osteosarcoma using population-based registries, United States, 1999-2008". J Registry Manag. 40 (2): 59–64. PMC 4476493. PMID 24002129.
- ↑ Foley JM, Scholten DJ, Monks NR, Cherba D, Monsma DJ, Davidson P, Dylewski D, Dykema K, Winn ME, Steensma MR (April 2015). "Anoikis-resistant subpopulations of human osteosarcoma display significant chemoresistance and are sensitive to targeted epigenetic therapies predicted by expression profiling". J Transl Med. 13: 110. doi:10.1186/s12967-015-0466-4. PMC 4419490. PMID 25889105.
- ↑ Huang X, Zhao J, Bai J, Shen H, Zhang B, Deng L, Sun C, Liu Y, Zhang J, Zheng J (June 2019). "Risk and clinicopathological features of osteosarcoma metastasis to the lung: A population-based study". J Bone Oncol. 16: 100230. doi:10.1016/j.jbo.2019.100230. PMC 6423404. PMID 30923668.
- ↑ Simpson S, Dunning MD, de Brot S, Grau-Roma L, Mongan NP, Rutland CS (October 2017). "Comparative review of human and canine osteosarcoma: morphology, epidemiology, prognosis, treatment and genetics". Acta Vet. Scand. 59 (1): 71. doi:10.1186/s13028-017-0341-9. PMC 5655853. PMID 29065898.
- ↑ 7.0 7.1 7.2 7.3 7.4 Moore DD, Luu HH (2014). "Osteosarcoma". Cancer Treat. Res. 162: 65–92. doi:10.1007/978-3-319-07323-1_4. PMID 25070231.
- ↑ Stern N, Sakji I, Defachelles AS, Lervat C, Ryckewaert T, Marliot G, Peugniez C, Deplanque D, Penel N (March 2017). "[Incidence and risk factors for ifosfamide-related encephalopathy in sarcoma patients]". Bull Cancer (in French). 104 (3): 208–212. doi:10.1016/j.bulcan.2016.11.007. PMID 27986268.
- ↑ Endicott AA, Morimoto LM, Kline CN, Wiemels JL, Metayer C, Walsh KM (June 2017). "Perinatal factors associated with clinical presentation of osteosarcoma in children and adolescents". Pediatr Blood Cancer. 64 (6). doi:10.1002/pbc.26349. PMID 27860191.
- ↑ Miller BJ, Cram P, Lynch CF, Buckwalter JA (July 2013). "Risk factors for metastatic disease at presentation with osteosarcoma: an analysis of the SEER database". J Bone Joint Surg Am. 95 (13): e89. doi:10.2106/JBJS.L.01189. PMC 3689260. PMID 23824394.
- ↑ Zhang HF, Yan JP, Zhuang YS, Han GQ (September 2015). "Association between angiogenic growth factor genetic polymorphisms and the risk of osteosarcoma". Genet. Mol. Res. 14 (3): 10524–9. doi:10.4238/2015.September.8.14. PMID 26400284.
- ↑ Osteosarcoma. U.S. Preventive Services Task Force.http://www.uspreventiveservicestaskforce.org/BrowseRec/Search?s=osteosarcoma
- ↑ Liu W, Zhao X, Zhang YJ, Fang GW, Xue Y (March 2018). "MicroRNA-375 as a potential serum biomarker for the diagnosis, prognosis, and chemosensitivity prediction of osteosarcoma". J. Int. Med. Res. 46 (3): 975–983. doi:10.1177/0300060517734114. PMC 5972241. PMID 29115164.
- ↑ Friebele JC, Peck J, Pan X, Abdel-Rasoul M, Mayerson JL (December 2015). "Osteosarcoma: A Meta-Analysis and Review of the Literature". Am J. Orthop. 44 (12): 547–53. PMID 26665241.
- ↑ Luetke A, Meyers PA, Lewis I, Juergens H (May 2014). "Osteosarcoma treatment - where do we stand? A state of the art review". Cancer Treat. Rev. 40 (4): 523–32. doi:10.1016/j.ctrv.2013.11.006. PMID 24345772.
- ↑ Parry MC, Laitinen M, Albergo J, Jeys L, Carter S, Gaston CL, Sumathi V, Grimer RJ (April 2016). "Osteosarcoma of the pelvis". Bone Joint J. 98-B (4): 555–63. doi:10.1302/0301-620X.98B4.36583. PMID 27037440.
- ↑ Yonemoto T, Hosono A, Iwata S, Kamoda H, Hagiwara Y, Fujiwara T, Kawai A, Ishii T (June 2015). "The prognosis of osteosarcoma occurring as second malignancy of childhood cancers may be favorable: experience of two cancer centers in Japan". Int. J. Clin. Oncol. 20 (3): 613–6. doi:10.1007/s10147-014-0729-8. PMID 25022788.
- ↑ Kager L, Tamamyan G, Bielack S (February 2017). "Novel insights and therapeutic interventions for pediatric osteosarcoma". Future Oncol. 13 (4): 357–368. doi:10.2217/fon-2016-0261. PMID 27651036.
- ↑ Cates JM (March 2017). "Comparison of the AJCC, MSTS, and Modified Spanier Systems for Clinical and Pathologic Staging of Osteosarcoma". Am. J. Surg. Pathol. 41 (3): 405–413. doi:10.1097/PAS.0000000000000774. PMID 28195881.
- ↑ 20.0 20.1 Biazzo A, De Paolis M (December 2016). "Multidisciplinary approach to osteosarcoma". Acta Orthop Belg. 82 (4): 690–698. PMID 29182106.
- ↑ Cates J (April 2018). "Modeling Continuous Prognostic Factors in Survival Analysis: Implications for Tumor Staging and Assessing Chemotherapy Effect in Osteosarcoma". Am. J. Surg. Pathol. 42 (4): 485–491. doi:10.1097/PAS.0000000000000995. PMID 29200101. Vancouver style error: initials (help)
- ↑ Jeys LM, Thorne CJ, Parry M, Gaston CL, Sumathi VP, Grimer JR (March 2017). "A Novel System for the Surgical Staging of Primary High-grade Osteosarcoma: The Birmingham Classification". Clin. Orthop. Relat. Res. 475 (3): 842–850. doi:10.1007/s11999-016-4851-y. PMC 5289182. PMID 27138473.
- ↑ Kumar R, Kumar M, Malhotra K, Patel S (February 2018). "Primary Osteosarcoma in the Elderly Revisited: Current Concepts in Diagnosis and Treatment". Curr Oncol Rep. 20 (2): 13. doi:10.1007/s11912-018-0658-1. PMID 29492676.
- ↑ 24.0 24.1 Kim HJ, Chalmers PN, Morris CD (February 2010). "Pediatric osteogenic sarcoma". Curr. Opin. Pediatr. 22 (1): 61–6. doi:10.1097/MOP.0b013e328334581f. PMID 19915470.
- ↑ 25.0 25.1 Ilaslan H, Schils J, Nageotte W, Lietman SA, Sundaram M (March 2010). "Clinical presentation and imaging of bone and soft-tissue sarcomas". Cleve Clin J Med. 77 Suppl 1: S2–7. doi:10.3949/ccjm.77.s1.01. PMID 20179183.
- ↑ 26.0 26.1 Wu PK, Chen WM, Lee OK, Chen CF, Huang CK, Chen TH (November 2010). "The prognosis for patients with osteosarcoma who have received prior manipulative therapy". J Bone Joint Surg Br. 92 (11): 1580–5. doi:10.1302/0301-620X.92B11.24706. PMID 21037356.
- ↑ 27.0 27.1 Obiedat H, Alrabadi N, Sultan E, Al Shatti M, Zihlif M (July 2018). "The effect of ERCC1 and ERCC2 gene polymorphysims on response to cisplatin based therapy in osteosarcoma patients". BMC Med. Genet. 19 (1): 112. doi:10.1186/s12881-018-0627-4. PMC 6035436. PMID 29980176.
- ↑ Osteosarcoma. surgwiki. http://www.surgwiki.com/wiki/Diseases_of_bone_and_joints#SURGERY_4
- ↑ Osteosarcoma. Dr Amir Rezaee ◉ and Dr Frank Gaillard ◉ et al. Radiopaedia.org 2015. http://radiopaedia.org/articles/osteosarcoma
- ↑ Osteosarcoma. Dr Amir Rezaee ◉ and Dr Frank Gaillard ◉ et al. http://radiopaedia.org/articles/osteosarcoma
- ↑ Osteosarcoma. Canadian Cancer Society. http://www.cancer.ca/en/cancer-information/cancer-type/bone/diagnosis/?region=bc